June 25, 2026 ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026 ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
